The University of Ljubljana is the oldest, largest, and internationally best ranked university in Slovenia, being among the first 500 or the first 3% of the world's best universities according to the ARWU. With over 63,000 enrolled undergraduate and graduate students, it is also among the largest universities in Europe. Wikipedia.
University of Ljubljana and University of Montenegro | Date: 2017-04-12
The present invention relates to a method for image processing comprising compressive sensing-based image filtering and intelligent removal of noise from images, and for image reconstruction/decompression, and to a device for carrying out said method. The system enables reconstruction of a natural image missing a great part of useful information. The method further enables filtering and removing of two types of noise from damaged natural images, that is a Gaussian noise and an impulse noise.
Prosen T.,University of Ljubljana
Physical Review Letters | Year: 2011
An exact and explicit ladder-tensor-network ansatz is presented for the nonequilibrium steady state of an anisotropic Heisenberg XXZ spin-1/2 chain which is driven far from equilibrium with a pair of Lindblad operators acting on the edges of the chain only. We show that the steady-state density operator of a finite system of size n is-apart from a normalization constant-a polynomial of degree 2n-2 in the coupling constant. Efficient computation of physical observables is facilitated in terms of a transfer operator reminiscent of a classical Markov process. In the isotropic case we find cosine spin profiles, 1/n2 scaling of the spin current, and long-range correlations in the steady state. This is a fully nonperturbative extension of a recent result. © 2011 American Physical Society.
Prosen T.,University of Ljubljana
Physical Review Letters | Year: 2011
An explicit matrix product ansatz is presented, in the first two orders in the (weak) coupling parameter, for the nonequilibrium steady state of the homogeneous, nearest neighbor Heisenberg XXZ spin 1/2 chain driven by Lindblad operators which act only at the edges of the chain. The first order of the density operator becomes, in the thermodynamic limit, an exact pseudolocal conservation law and yields-via the Mazur inequality-a rigorous lower bound on the high-temperature spin Drude weight. Such a Mazur bound is a nonvanishing fractal function of the anisotropy parameter Δ for |Δ|<1. © 2011 American Physical Society.
Prosen T.,University of Ljubljana
Physical Review Letters | Year: 2014
We discuss the current carrying nonequilibrium steady state of an open fermionic Hubbard chain that is strongly driven by Markovian incoherent processes localized at the chain ends. An explicit form of an exact many-body density operator for any value of the coupling parameter is presented. The structure of a matrix product form of the solution is encoded in terms of a novel diagrammatic technique that should allow for generalization to other integrable nonequilibrium models. © 2014 American Physical Society.
Vrtovec B.,University of Ljubljana
Circulation research | Year: 2013
CD34+ transplantation in dilated cardiomyopathy was associated with short-term improvement in left ventricular ejection fraction and exercise tolerance. We investigated long-term effects of intracoronary CD34+ cell transplantation in dilated cardiomyopathy and the relationship between intramyocardial cell homing and clinical response. Of 110 dilated cardiomyopathy patients, 55 were randomized to receive CD34+ stem cell transplantation (SC group) and 55 received no cell therapy (controls). In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect. At baseline, 2 groups did not differ in age, sex, left ventricular ejection fraction, or N-terminal B-type natriuretic peptide levels. At 5 years, stem cell therapy was associated with increased left ventricular ejection fraction (from 24.3 ± 6.5% to 30.0 ± 5.1%; P=0.02), increased 6-minute walk distance (from 344 ± 90 m to 477 ± 130 m; P<0.001), and decreased N-terminal B-type natriuretic peptide (from 2322 ± 1234 pg/mL to 1011 ± 893 pg/mL; P<0.01). Left ventricular ejection fraction improvement was more significant in patients with higher myocardial homing of injected cells. During follow-up, 27 (25%) patients died and 9 (8%) underwent heart transplantation. Of the 27 deaths, 13 were attributed to pump failure and 14 were attributed to sudden cardiac death. Total mortality was lower in the SC group (14%) than in controls (35%; P=0.01). The same was true of pump failure (5% vs. 18%; P=0.03), but not of sudden cardiac death (9% vs. 16%; P=0.39). Intracoronary stem cell transplantation may be associated with improved ventricular function, exercise tolerance, and long-term survival in patients with dilated cardiomyopathy. Higher intramyocardial homing is associated with better stem cell therapy response.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: LCE-06-2015 | Award Amount: 17.86M | Year: 2016
By 2020, several areas of the HVAC pan-European transmission system will be operated with extremely high penetrations of Power Electronics(PE)-interfaced generators, thus becoming the only generating units for some periods of the day or of the year due to renewable (wind, solar) electricity. This will result in i) growing dynamic stability issues for the power system (possibly a new major barrier against future renewable penetration), ii) the necessity to upgrade existing protection schemes and iii) measures to mitigate the resulting degradation of power quality due to harmonics propagation. European TSOs from Estonia, Finland, France, Germany, Iceland, Ireland, Italy, Netherlands, Slovenia, Spain and UK have joined to address such challenges with manufacturers (Alstom, Enercon, Schneider Electric) and universities/research centres. They propose innovative solutions to progressively adjust the HVAC system operations. Firstly, a replicable methodology is developed for appraising the distance of any EU 28 control zone to instability due to PE proliferation and for monitoring it in real time, along with a portfolio of incremental improvements of existing technologies (the tuning of controllers, a pilot test of wide-area control techniques and the upgrading of protection devices with impacts on the present grid codes). Next, innovative power system control laws are designed to cope with the lack of synchronous machines. Numerical simulations and laboratory tests deliver promising control solutions together with recommendations for new PE grid connection rules and the development of a novel protection technology and mitigation of the foreseen power quality disturbances. Technology and economic impacts of such innovations are quantified together with barriers to be overcome in order to recommend future deployment scenarios. Dissemination activities support the deployment schemes of the project outputs based on knowledge sharing among targeted stakeholders at EC level.
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.75M | Year: 2017
TREATMENT is a Marie Sklodowska Curie Innovative Training Network proposal directly addressing the need for high-level training and career paths in risk evaluation of drug induced metabolic dysfunctions, a relevant aspect, so far unexplored by traditional toxicology studies, but urgently needed to challenge current severe limitations of health care interventions in mental disorders. These patients require life-long medications that subsequently trigger metabolic diseases with a strong negative impact on their health and well-being. To achieve this, and improve adherence to treatments, we will evaluate how short-term antipsychotic drug responses impact long-term metabolic control to identify and validate biomarkers with clinically predictive value for targeting drug induced metabolic dysfunctions. This effort will have added commercial value by enabling the design of predictive marker kits for testing adverse secondary metabolic effects of drugs to be used in pharmacological and medical practice. TREATMENT will provide multidisciplinary knowledge, capabilities and tools to implement this ambitious strategy by the training of young scientists in a program that combines pharmacology, metabolism and mental health research with strategies for product and tool design and validation. Our ultimate goal is to empower the intersectorial and trans-national employability of young scientists across academic, public and private sectors to foster the development and implementation of personalized medicine tools that will provide effective treatment regimens for life long health-care interventions and decrease the risk for development of chronic metabolic diseases.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: BIOTEC-03-2016 | Award Amount: 5.06M | Year: 2017
TOPCAPI will exploit the natural fabrication power of actinomycetes as microbial cell factories to produce three high value compounds: GE2270, a starter compound for the semi-synthesis of NAI-Acne, a new topical anti-acne drug in Phase II clinical trials; 6-desmethyl-tetracycline (6DM-TC) and 6-desmethyl 6-deshydro tetracycline (6DM6DH-TC), intermediates for semi-synthetic conversion to medically important type II polyketide tetracyclines (TC), e.g. minocycline, tigecycline, and the novel omadacycline, which is in Phase III clinical trials, to be used against Methicillin-resistant Staphylococcus aureus infections. Our work will focus on two bacterial host species: Streptomyces coelicolor and Streptomyces rimosus. These host species will be characterised using systems biology approaches, applying integrated data analysis to transcriptomics and metabolomics experiments, combined with predictive mathematical modelling to drive the rapid improvement of these microbial cell factories for industrial drug production using advanced metabolic and biosynthetic engineering approaches. At the same time, we will establish an expanded toolbox for the engineering of actinomycete bacteria as cell factories for other high added-value compounds. In the proposed 4-year project, we will: 1. Host engineer two new actinomycete strains for industry-level improved heterologous compound production through integrating systems biology-driven strain design and state-of-the-art genome editing. 2. Engineer the biosynthesis pathways to obtain high-efficiency synthesis of GE2270 and new pathway variants for 6DM-TC and 6DM6DH-TC as well as improve its production purity. 3. Optimise the expression of the engineered target pathways in pre-engineered strains to achieve industrially viable production levels of 1 g/L for GE2270 and 24 g/L for 6DM-TC, while creating a complete novel production strain for 6DM6DH-TC.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: EINFRA-11-2016 | Award Amount: 16.11M | Year: 2017
PRACE, the Partnership for Advanced Computing is the permanent pan-European High Performance Computing service providing world-class systems for world-class science. Systems at the highest performance level (Tier-0) are deployed by Germany, France, Italy and Spain providing researchers with over 11 billion core hours of compute time. HPC experts from 25 member states enabled users from academia and industry to ascertain leadership and remain competitive in the Global Race. Currently PRACE is in transition to PRACE 2, the successor of the initial five year period. The objectives of PRACE-5IP are to build on and seamlessly continue the successes of PRACE and start new innovative and collaborative activities proposed by the consortium. These include: assisting the transition to PRACE 2 including an analysis of Trans National Access; strengthening the internationally recognised PRACE brand; continuing and extend advanced training which so far provided more than 18 800 persontraining days; preparing strategies and best practices towards Exascale computing; coordinating and enhancing the operation of the multi-tier HPC systems and services; and supporting users to exploit massively parallel systems and novel architectures. A high level Service Catalogue is provided. The proven project structure will be used to achieve each of the objectives in 6 dedicated work packages. The activities are designed to increase Europes research and innovation potential especially through: seamless and efficient Tier-0 services and a pan-European HPC ecosystem including national capabilities; promoting take-up by industry and new communities and special offers to SMEs; implementing a new flexible business model for PRACE 2; proposing strategies for deployment of leadership systems; collaborating with the ETP4HPC, CoEs and other European and international organisations on future architectures, training, application support and policies. This will be monitored through a set of KPIs.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: ICT-25-2016-2017 | Award Amount: 4.62M | Year: 2017
The global goal of the CYBERLEGs Plus Plus project is to validate the technical and economic viability of the powered robotic ortho-prosthesis developed within the framework of the FP7-ICT-CYBERLEGs project as a means to enhance/restore the mobility of transfemoral amputees and to enable them to perform locomotion tasks such as ground-level walking, walking up and down slopes, climbing/descending stairs, standing up, sitting down and turning in scenarios of real life. Restored mobility will allow amputees to perform physical activity thus counteracting physical decline and improving the overall health status and quality of life. This consortium will pursue the achievement of the global goal by addressing four specific innovation objectives. 1) Further developments of the existing CYBERLEGs hardware modules, namely the 2-degree-of-freedom active transfemoral prosthesis, the active wearable orthotic device, and the wearable sensory apparatus. 2) Further developments of the existing multi-layered CYBERLEGs control system, to enhance its reliable use in real-life scenarios. 3) Carrying out two multi-centre clinical studies, that validate the therapeutic potentialities and the economic viability of a robotic ortho-prosthesis which restores the amputees locomotion abilities in scenarios of activities of daily living. 4) Implementation of a 3-phase strategy to foster the start of the market exploitation within the time frame of the CLs\\ project. This proposal focuses on the demonstration in an operational environment (TRL=7) from both the technical and economic viability view point of a modular robotics technology for healthcare, with the ultimate goal of fostering its market exploitation. The proposals involve players from academia, end users, as well as robotics and healthcare industry. Therefore this proposal fits the specific challenge of the scope c of the call H2020-ICT-25-2016-2017.